Enteropathy-associated T-cell lymphoma (EATL) is associated with refractory celiac disease (RCD).
1,2 Approximately, 50% of patients with CD are diagnosed in adulthood; of them, 2-5% develop RCD. RCD patients comprise two groups: one with immunophenotypically aberrant intraepithelial lymphocytes (RCDII) and one without these cells (RCDI), the cutoff being 20%. 2 Aberrant intraepithelial lymphocytes are characterized by the lack of surface expression of CD3 and often also CD8. Overall, 60-80% of RCDII patients develop EATL within 5 years. 3 Enteropathy-associated T-cell lymphoma is almost invariably lethal, although high-dose chemotherapy followed by Auto-SCT might improve survival. 3 Experience with myeloablative or reduced-intensity conditioned (RIC) Allo-SCT in T-cell non-Hodgkin's lymphoma is limited, but promising. 4 We report the first two celiac patients with EATL in whom we performed Allo-RIC-SCT from an HLA-identical sibling donor.
Case 1
A 66-year-old man, recently diagnosed with CD, presented with weight loss and night sweats. Abdominal CT showed increased jejunal wall thickness and mesenterial lymphadenopathy, suggestive of EATL.
5 Double balloon enteroscopy revealed ulcerative jejunitis and stenosis due to multiple masses. A diagnosis of EATL was confirmed by biopsies. BM investigation revealed 15% aberrant T cells (CD3 þ , CD7À). 2 He underwent a resection of the involved small bowel segment, with primary anastomosis. After surgery there were no signs of short-bowel syndrome and a strict gluten-free diet was started. Post-surgical FDG-PET evaluation showed multiple lymph nodes suspicious of residual EATL. Treatment with six cycles of CHOP chemotherapy was initiated and subsequent FDG-PET showed CR.
HLA typing identified two siblings as fully matched donors. One of them was diagnosed with CD during pre-transplant screening. The other sibling, with a negative celiac serotype, was therefore selected. At 6 weeks after the last chemotherapy, Allo-RIC-SCT was performed following conditioning with fludarabine (25 mg/m 2 ) and CY (500 mg/m 2 ) (flu-cy) for 5 consecutive days. A total of 4.8 Â 10 6 CD34 þ cells/kg were infused after conditioning. Donor chimerism after 1 and 2 months was 83 and 90%, respectively.
At 2 months after Allo-SCT the patient developed a relapse of EATL. Rapid deterioration precluded further treatment, and the patient died 3 months after Allo-SCT.
Case 2
A 61-year-old man was admitted with perforation of the jejunum. He underwent partial surgical resection of the jejunum. Pathological examination revealed perforation due to EATL (Marsh IIIA). BM investigation revealed 0.01% aberrant T cells.
After surgery there were no signs of short-bowel syndrome and a strict gluten-free diet was initiated. Postsurgical FDG-PET evaluation showed intense uptake in the left upper part of the abdomen. There were no other signs of EATL. After six cycles of CHOP chemotherapy FDG-PET showed CR.
The patient was subsequently transplanted from an HLA compatible matched sibling 2 months after finishing chemotherapy. A total of 8.3 Â 10 6 CD34 þ cells/kg were infused after conditioning. At 1 month after transplantation, donor chimerism was 23% in peripheral blood and 19% in BM.
At 6 weeks after transplantation, the patient developed non-specific abdominal complaints and a rise in lactate dehydrogenase. As relapse was suspected, immunosuppressive medication was discontinued. After 2 weeks, relapse of EATL was confirmed. His condition deteriorated quickly and 9 weeks after Allo-SCT the patient died.
To date, treatment of EATL is disappointing. Recently, several studies with high-dose chemotherapy and Auto-SCT have been published. These regimens showed improving results, but only in selected patients. Bishton and Haynes 3 illustrated the beneficial effect of high-dose chemotherapy in six patients. In total, 4 patients are still alive after 2-4 years follow-up. Other reports, however, showed less favorable results. [6] [7] [8] New strategies are therefore urgently needed.
Theoretically, Allo-SCT might be a treatment option for patients diagnosed with EATL. In a prospective, multicenter phase II trial, a total of 170 elderly (X45 years) patients with relapsed or refractory lymphomas of all types (including 14% aggressive T-cell non-Hodgkin's lymphoma) received Allo-RIC-SCT from HLA-identical sibling donors. This procedure was found to be feasible and effective. A trend toward a higher relapse rate was observed in patients with aggressive lymphoma in PR or with refractory disease before transplantation. Withdrawal of CYA contributed to the clinical response. Median time to progression was 6 months. 9 In an earlier study, a poor outcome of Allo-RIC-SCT in patients with chemoresistant and high-grade lymphomas (including T-cell non-Hodgkin's lymphoma) was reported. 10 Although this retrospective study failed to show an effect of intensity of conditioning, it was hypothesized that these patients benefited less from Allo-SCT, as the beneficial effect of GVL takes a few months to develop. Donor lymphocyte infusion was successful, illustrating a GVL effect. 10 We decided to offer Allo-RIC-SCT to chemosensitive patients in CR using our flu-cy conditioning scheme. As HLA DQ2 and DQ8 are associated with CD, the donor search needed special consideration to exclude donors with CD by serological screening.
The two cases presented are the first EATL patients treated with Allo-RIC-SCT. The experimental setting led to the selection of HLA-identical siblings only. Although both patients were chemosensitive and in CR before transplantation, they developed relapse of EATL within a few weeks after transplantation. As a GVL effect could not have occurred, the conditioning probably was not sufficiently potent to buy time.
Possibly more intensive consolidation, for instance the Bishton schedule, is necessary to improve current results in this highly aggressive lymphoma. 3 Moreover, it may be that introducing GVL in an earlier stage, established by more rapid exclusion of immunosuppressive medication, might improve results.
In conclusion, this first report of Allo-RIC-SCT in patients with EATL and CD illustrates its feasibility but also disappointing results in two patients in CR in excellent condition pre-transplant. It is possible that more intensive consolidation is needed to improve results.
